ACRS
Aclaris Therapeutics, Inc.
Biotechnology · Healthcare · United States
3.97
close · 2026-10-30
value
29
cheaper than peers29
quality
58
stronger fundamentals58
ranked against
Biotechnology (commercial)
value
quality
162 peerswide variation
Value inputs
| measure | company | vs peers |
| cash flow yield, latest year | -7.7% | 56 |
| cash flow yield, 1 year ago | -9.1% | 52 |
| earnings yield, latest year | -13.4% | 47 |
| cash flow yield, 2 years ago | -12.9% | 43 |
| cash flow yield, 3 years ago | -11.1% | 42 |
| price to book | 4.46× | 38 |
| earnings yield, 2 years ago | -32.0% | 37 |
| earnings yield, 3 years ago | -33.5% | 37 |
| earnings yield, 1 year ago | -43.1% | 29 |
| price to sales | 73.54× | 17 |
10 of 12 measures available
Quality inputs
| measure | company | vs peers |
| debt to equity | 1.4% | 91 |
| revenue growth | 37.2% | 59 |
| return on equity | -48.4% | 50 |
| operating margin | -1111.8% | 19 |
4 of 4 measures available
Facts
| market cap | $615M |
| free cash flow | -$32.2M |
| employees | 69 |
| first trade | 2015-10-06 |
| next earnings | 2026-08-06 |
| fundamentals updated | 2026-08-06 |
Annual history
| measure | 2025 | 2024 | 2023 | 2022 |
| diluted eps | -0.53 | -1.71 | -1.27 | -1.33 |
| free cash flow | -$47.2M | -$56.0M | -$79.6M | -$68.2M |
| net income | -$64.9M | -$132.1M | -$88.5M | -$86.9M |
| revenue | $7.8M | $18.7M | $31.2M | $29.8M |
| unusual items | -$2.3M | -$89.4M | $19.0M | -$4.7M |